Exenatide extended-release: a once-weekly option for patients with type 2 diabetes.
Exenatide extended-release is a new long-acting glucagon-like peptide-1 agonist that may be an attractive option for patients desiring to lose weight, who are prone to hypoglycemic episodes, and who have not achieved desired glycemic control with current therapy.
At Presbyterian College School of Pharmacy in Clinton, S.C., Zachary L. Anderson is an assistant professor of pharmacy practice and Jennifer N. Clements is an associate professor of pharmacy practice. The authors have disclosed no potential conflicts of interest, financial or otherwise.
Zachary L
ZL
Anderson
Jennifer N
JN
Clements
D003692:Delayed-Action Preparations / Q000008:administration & dosage; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004334:Drug Administration Schedule; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D010455:Peptides / Q000008:administration & dosage*; D014688:Venoms / Q000008:administration & dosage*
D003692:Delayed-Action Preparations; D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D000077270:Exenatide